Strategic positioning Target hypertension treatment market with perivascular alcohol denervation using the Peregrine System, highlighting a potentially superior reach to renal nerves compared to energy-based methods, and position as a clinically-focused, minimally invasive solution in both Europe post-market data and planned US randomized trials.

Regulatory momentum Leverage FDA 510(k) clearance for perivascular infusion and CE conformity in Europe to pursue early-adopter clinical centers and multi-country deployment opportunities, aligning sales efforts with ongoing post-market studies and upcoming U.S. pivotal trial plans.

Financial backing Capitalize on substantial funding runway from recent Series D and overall funding, enabling expansion to additional clinical sites, larger pilot programs, and accelerated on-market education and training initiatives for interventional cardiology and nephrology teams.

Clinical evidence Drive customer conversations around real-world outcomes from ongoing Europe post-market study and planned US randomized trials to demonstrate safety, efficacy, and potential long-term blood pressure reductions, supporting reimbursement discussions.

Key stakeholders Engage with executive leadership and clinical trial sites identified in prior press, focusing outreach to hospitals, vascular specialties, and hypertension programs, while aligning with investors’ interest in Michigan-based innovation and scalable medical device platforms.